Showing 3301-3310 of 5773 results for "".
- Oculis to Present a Late-Breaking Abstract at Euretina on Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edemahttps://modernod.com/news/oculis-to-present-a-late-breaking-abstract-at-euretina-on-phase-3-stage-1-diamond-trial-results-for-diabetic-macular-edema/2481867/Oculis announced that the positive readout from Stage 1 of its phase 3 DIAMOND trial of OCS-01 in patients with diabetic macular edema (DME) will be presented as a late-breaking abstract at the 23rd Euretina Congress, taking place October 5-8, 2023 in Amsterdam, the Netherlands.
- Bausch + Lomb Completes Acquisition of Xiidrahttps://modernod.com/news/bausch-lomb-completes-acquisition-of-xiidra/2481861/Bausch + Lomb announced it has completed its acquisition of Xiidra (lifitegrast ophthalmic solution 5%), a non-steroid eye drop approved to treat the signs and symptoms of dry eye disease (DED) focusing on inflammation associated with dry eye. In June, Bausch + Lomb&
- Viatris Launches First National Direct to Consumer Campaign for Dry Eye Nasal Spray Tyrvayahttps://modernod.com/news/viatris-launches-first-national-direct-to-consumer-campaign-for-dry-eye-nasal-spray-tyrvaya/2481860/After nearly 2 years of educational programs to introduce Tyrvaya (varenicline solution) Nasal Spray to eye care professionals, the Viatris Eye Care Division announced it is rolling out a nationwide, multi-channel campaign. The new campaign, entitled “It’s Not Another Drop,&
- Zeiss and Boehringer Ingelheim Partner to Develop Early Detection of Eye Diseases and Prevent Vision Losshttps://modernod.com/news/zeiss-and-boehringer-ingelheim-partner-to-develop-early-detection-of-eye-diseases-and-prevent-vision-loss/2481859/Zeiss Medical Technology and Boehringer Ingelheim announced a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with eye diseases. The partnership aims to bring togeth
- Harrow Health Changes Corporate Name to Harrow Inc.https://modernod.com/news/harrow-health-changes-corporate-name-to-harrow-inc/2481858/Harrow announced that effective today, it has changed its corporate name from “Harrow Health Inc.” to “Harrow Inc.” to align with the company’s current 5-year strategic plan, which includes an exclusive focus on eye care pharmaceuticals. “Gi
- Prevent Blindness Names Ed Buffington, GPN Technologies, as the 2024 Person of Vision Award Recipienthttps://modernod.com/news/prevent-blindness-names-ed-buffington-gpn-technologies-as-the-2024-person-of-vision-award-recipient/2481856/Prevent Blindness announced that the
- LumiThera Receives NIH Grant to Support Dry AMD Trialhttps://modernod.com/news/lumithera-receives-nih-grant-to-support-dry-amd-trial/2481855/LumiThera announced it is a recipient of a small business innovative research (SBIR) phase 2 grant from the National Institute of Health (NIH) of up to $2.3 million in funding over 2 years. The NIH/NEI grant supports an open-label human clinical trial in intermediate dry
- Ocuphire Pharma and Viatris Receive FDA Approval of Ryzumvi for the Reversal of Pharmacologically-Induced Mydriasishttps://modernod.com/news/ocuphire-pharma-and-viatris-receive-fda-approval-of-ryzumvi-for-the-reversal-of-pharmacologically-induced-mydriasis/2481852/Ocuphire Pharma and Viatris announced that the FDA has approved Ryzumvi (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents.
- BostonSight Receives MMAP Grant to Expand and Automate Scleral Lens Manufacturinghttps://modernod.com/news/bostonsight-receives-mmap-grant-to-expand-and-automate-scleral-lens-manufacturing/2481848/BostonSight, a nonprofit healthcare organization that advances the treatment of diseased and damaged corneas and dry eye, announced it has received a $200,000 manufacturing grant from the Massachusetts Manufacturing Accelerate Program (MMAP) to advance its scleral lens manufacturing capabili
- Dopavision Completes Enrollment for MyopiaX-1 Trialhttps://modernod.com/news/dopavision-completes-enrollment-for-myopiax-1-trial/2481847/Dopavision, a clinical stage company developing solutions for myopia, announced the completion of enrollment in its MyopiaX-1 trial (NCT04967287). MyopiaX-1 is a randomized, active-controlled trial to evaluate the saf